Clinical Trials Logo

Richter's Transformation clinical trials

View clinical trials related to Richter's Transformation.

Filter by:

NCT ID: NCT06043674 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

A Ph 2 Study of Glofitamab Alone or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation

Start date: January 22, 2024
Phase: Phase 2
Study type: Interventional

This research is being done to evaluate Glofitamab by itself or in combination with Polatuzumab Vedotin or Atezolizumab as possible treatments for Chronic Lymphocytic Leukemia (CLL) that has transformed into Richter's Transformation (RT). The names of the study drugs involved in this research study are: - Glofitamab (a T-cell bispecific humanized monoclonal antibody) - Obinutuzumab (a humanized glycoengineered type II anti-CD20 monoclonal antibody) - Polatuzumab vedotin (an antibody-drug conjugate) - Atezolizumab (a humanized immunoglobulin monoclonal antibody) - Tocilizumab (a recombinant, humanized, anti-human monoclonal antibody)

NCT ID: NCT05294731 Recruiting - Clinical trials for Mantle Cell Lymphoma

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

Start date: March 24, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study aims to explore the recommended phase 2 dose and evaluate the safety, tolerability and preliminary antitumor activity of BGB-16673 monotherapy at the recommended Phase 2 dose for the selected B-cell malignancy expansion cohorts

NCT ID: NCT04806035 Active, not recruiting - Follicular Lymphoma Clinical Trials

Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Start date: April 23, 2021
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to determine the recommended phase 2 dose (RP2D) and characterize the safety profile of TG-1801. As per protocol v3.0, ublituximab will be discontinued.

NCT ID: NCT04305444 Recruiting - Follicular Lymphoma Clinical Trials

Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

Start date: April 24, 2020
Phase: Phase 2
Study type: Interventional

Targeted drug therapies have greatly improved outcomes for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma. However, single drug therapies have limitations, therefore, the current study is evaluating a novel oral combination of targeted drugs as a way of overcoming these limitations. This study will determine the efficacy of the triple combination therapy, DTRM-555, in patients with R/R CLL or R/R non-Hodgkin's lymphoma.

NCT ID: NCT03778073 Terminated - Clinical trials for B-cell Non Hodgkin Lymphoma

Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma

Start date: April 17, 2019
Phase: Phase 1
Study type: Interventional

Phase 1 open label, multi-center, dose-escalation study for individuals with relapsed or refractory B-cell Non Hodgkin's Lymphoma.

NCT ID: NCT03162536 Active, not recruiting - Clinical trials for Chronic Lymphocytic Leukemia

A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

Start date: June 26, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This study aims to evaluate the safety, tolerability, pharmacodynamic, and pharmacokinetic (PK) of nemtabrutinib (formerly ARQ 531) tablets in selected participants with relapsed or refractory hematologic malignancies. No formal hypothesis testing will be performed for this study.

NCT ID: NCT03153514 Terminated - Clinical trials for Chronic Lymphocytic Leukemia

Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell Transplantation

CLLTX1
Start date: November 13, 2017
Phase: Phase 2
Study type: Interventional

The primary objective of the study is to evaluate the feasibility, efficacy and safety of an obinutuzumab containing conditioning regimen for poor risk CLL patients and patients with Richter's transformation requiring an allogeneic stem cell transplantation.

NCT ID: NCT03121534 Terminated - Clinical trials for Hematopoietic/Lymphoid Cancer

Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation

Start date: June 22, 2017
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if blinatumomab can help to control Richter Transformation (RT, a type of blood cancer). The safety of this drug will also be studied. This is an investigational study. Blinatumomab is FDA approved and commercially available for the treatment of acute lymphoblastic leukemia (ALL). It is investigational to use blinatumomab to treat patients with RT. The study doctor can explain how the study drug is designed to work. Up to 21 participants will be enrolled in this study. All will take part at MD Anderson.

NCT ID: NCT02863692 Recruiting - CLL Clinical Trials

Registry of the German CLL Study Group

CLL-Registry
Start date: August 2013
Phase:
Study type: Observational [Patient Registry]

Long term follow-up of patients with chronic lymphocytic leukemia (CLL), B-prolymphocytic leukemia (B-PLL), T-cell prolymphocytic leukemia (T-PLL), Small lymphocytic lymphoma (SLL), T/Natural Killer large granular lymphocyte leukemia (T or NK-LGL), Hairy cell leukemia (HCL) and Richter's transformation

NCT ID: NCT02378038 Terminated - Clinical trials for Richter's Transformation

PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)

Start date: August 2015
Phase: Phase 2
Study type: Interventional

This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. It is a multi-center, single-arm, 2-stage, open-label phase II investigation of PNT2258 to characterize anti-tumor activity and collect safety data on patients with Richter's Transformation.